[PS2] Presidential Session 2
【E】

[PS2-1] Trastuzumab Deruxtecan vs T-DM1 in HER2+ mBC in Asian Subgroup: Results of the Randomized Phase 3 Study DESTINY-Breast03

^○Seock-Ah Im¹, Binghe Xu², Sung-Bae Kim³, Wei-Pang Chung⁴, Yeon Hee Park⁵, Min-Hwan Kim⁶, Ling-Ming Tseng⁷, Chi-Feng Chung⁸, Chiun-Sheng Huang⁹, Jee Hyun Kim¹⁰, Joanne Wing Yan Chiu¹¹, Toshinari Yamashita¹², Wei Li¹³, Caleb Lee¹⁴, Soichiro Nishijima¹⁵, Kyohei Hamada¹⁵, Yuji Nishiyama¹⁵, Masahiro Sugihara¹⁵, Javier Cortés^16,17,18, Hiroji Iwata¹⁹ (1.Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea, 2.Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, 3.Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, 4.Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 5.Samsung Medical Center, Seoul, Republic of Korea, 6.Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, 7.Taipei Veterans General Hospital, Taipei, Taiwan, 8.Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, 9.National Taiwan University Hospital, Taipei, Taiwan, 10.Seoul National University Bundang Hospital, Seoul National University College of Medicine, Republic of Korea, 11.Queen Mary Hospital, Hong Kong, China, 12.Kanagawa Cancer Center, Kanagawa, Japan, 13.The First Hospital of Jilin University, Jilin, China, 14.Daiichi Sankyo, Inc., NJ, USA, 15.Daiichi Sankyo, Co., Ltd., Tokyo, Japan, 16.International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain, 17.Scientific Department, Medica Scientia Innovation Research (MedSIR), Valencia, Spain, 18.Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, 19.Aichi Cancer Center Hospital, Aichi, Japan)